Donis Canet F, Sánchez Gallego M D, Arias Fúnez F, Duque Ruíz G, Laso I, Brasero Burgos J, Lorca Álvaro J, Gómez Dos Santos V, Rodríguez Patrón R, Burgos Revilla F J
Departamento de Urología, Hospital Ramón y Cajal, Madrid, España.
Departamento de Urología, Hospital Ramón y Cajal, Madrid, España.
Actas Urol Esp (Engl Ed). 2018 Jul-Aug;42(6):355-364. doi: 10.1016/j.acuro.2017.06.005. Epub 2017 Aug 18.
The increasingly early diagnosis of prostate cancer requires a search for therapeutic alternatives with good oncological results that in turn facilitate a good long-term quality of life. This review analyses 2 minimally invasive therapies for treating localised prostate cancer in terms of oncological and functional results, as well as the complications resulting from the therapies.
A systematic literature review was conducted of the treatment of localised prostate cancer with 2 ablative techniques as the primary therapy: cryosurgery or cryotherapy and high intensity focused ultrasound (HIFU). We included patients who underwent procedures that included the entire gland, with hemiablation or focal therapy, which were indicated for low to intermediate-risk prostate cancer according to the D'Amico criteria. We excluded patients with high-risk prostate cancer and those who underwent any prior treatment for prostate cancer.
After conducting the literature search and excluding the studies that did not meet the protocol criteria, we reviewed a total of 14 studies, with a total of 350 patients treated using cryotherapy and 1107 treated with HIFU. All studies were either prospective or retrospective and were not randomised. The patients' mean age was younger than 75 years. Overall, the rate of disease recurrence in the patients treated with cryotherapy varied between 13.2% and 26%, while the rate for those treated with HIFU varied between 7.3% and 67.9%. The overall demonstrated continence at 12 months was 97.6-100% for cryotherapy and 96-100% for HIFU. In terms of sexual potency rates, cryotherapy showed complete potency at 12 months for 86-100% of the patients treated with focal cryotherapy and slightly lower rates for hemiablation (76.9-100%) and total therapy (39%). HIFU showed potency rates of 89%, 52-80% and 33-78% for focal therapy, hemiablation and total therapy, respectively.
Both techniques have comparable functional results, although the somewhat poorer oncological results for HIFU reflect a steeper learning curve, which could lead to its use in centres with high volumes of patients.
前列腺癌的诊断日益提早,这就需要寻找具有良好肿瘤学效果且能促进长期良好生活质量的治疗替代方案。本综述从肿瘤学和功能结果以及治疗引发的并发症方面,分析了两种用于治疗局限性前列腺癌的微创疗法。
对以两种消融技术作为主要疗法治疗局限性前列腺癌进行了系统的文献综述:冷冻手术或冷冻疗法以及高强度聚焦超声(HIFU)。我们纳入了接受包含整个腺体的手术、半消融或局部治疗的患者,这些患者根据达米科标准被判定为低至中度风险的前列腺癌。我们排除了高危前列腺癌患者以及之前接受过任何前列腺癌治疗的患者。
在进行文献检索并排除不符合方案标准的研究后,我们共回顾了14项研究,其中共有350例患者接受了冷冻疗法治疗,1107例接受了HIFU治疗。所有研究均为前瞻性或回顾性研究,且未进行随机分组。患者的平均年龄小于75岁。总体而言,接受冷冻疗法治疗的患者疾病复发率在13.2%至26%之间,而接受HIFU治疗的患者复发率在7.3%至67.9%之间。冷冻疗法在12个月时总体控尿率为97.6% - 100%,HIFU为96% - 100%。在性功能恢复率方面,冷冻疗法显示,接受局部冷冻治疗的患者在12个月时有86% - 100%完全恢复性功能,半消融(76.9% - 100%)和全腺治疗(39%)的恢复率略低。HIFU在局部治疗、半消融和全腺治疗后的性功能恢复率分别为89%、52% - 80%和33% - 78%。
两种技术具有相当的功能结果,尽管HIFU的肿瘤学结果稍差,这反映出其学习曲线较陡,这可能导致其在大量患者的中心使用。